DUBLIN - New Facility Part of Ambitious Expansion Plans at Central Manchester University Hospitals Foundation Trust Campus
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a collaborative agreement with the Central Manchester University Hospitals Foundation (CMFT) to develop a purpose built translational medicine facility.
The new facility will form part of an ambitious expansion plan being undertaken by Central Manchester University Hospitals Foundation Trust (CMFT) to develop the existing Manchester Royal Infirmary (MRI) campus. This re-development plan has already delivered Britain’s largest children’s hospital, which is due to open later in 2009. The remainder of the campus development is due for completion by April 2012 and will house an ICON-designed state-of-the-art Translational Medicine Unit. In the interim period ICON will transfer its current clinical pharmacology services into dedicated clinical research facilities on the Manchester Royal Infirmary site.
Commenting on the announcement, Dr Thomas Frey, President, ICON Development Solutions, said “We are delighted to be collaborating with the CMFT and the Manchester Academic Health Centre to continue to develop the region as an international centre of excellence in translational medicine. Moving to a hospital-based setting also meets the needs of our customers who are increasingly looking to run their first-in-human studies in hospital environments.”
Mike Deegan, Chief Executive of the CMFT added: “Our aim is to build upon our investments in facilities and high calibre clinical academic staff to consolidate our reputation as a leading international research hospital. This exciting new collaboration with ICON is a major step for the Trust and will accelerate the translation of research discoveries into new medicines. We look forward to working with the highly regarded ICON team.”
CMFT is a member of the Manchester Academic Health Science Centre (MAHSC) which is one of only five centres designated by the Department of Health as a centre of excellence in applying health research and education into healthcare. Through the collaboration ICON will share expertise and has access to the facilities of the other NHS members and the University of Manchester. Commenting on the collaboration, Linda Magee, Chief Operating Officer, MAHSC said “ICON is one of MAHSC’s selected industry partners and we are delighted they are developing their facilities with one of the MAHSC members, CMFT. As well as ICON’s complementary capabilities in clinical trials, we greatly value their commitment and contribution to education and training for clinical academics.”
Dr Allison Jeynes-Ellis, Medical and Innovation Director at the Association of the British Pharmaceutical Industry (ABPI), said: “This is an example of the type of collaboration between industry, academia and the NHS that the ABPI is seeking to encourage and which we believe will help drive forward translational medicine, building on the strength of the pharmaceutical, science and clinical base in the UK.”
About ICON plc ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has over 7,100 employees, operating from 71 locations in 38 countries. Further information is available at www.iconplc.com
About Central Manchester University Hospitals Foundation Trust
The Trust was established in April 2001 following public consultation to merge the then Central Manchester Healthcare NHS Trust and Manchester Children’s Hospitals NHS Trust. It was authorised as a Foundation Trust by Monitor and from January 1 2009 became known as Central Manchester University Hospitals NHS Foundation Trust. It now has 1,208 beds across six hospitals and approximately 8,000 staff.
www.cmft.nhs.uk/
About Manchester Academic Health Science Centre
The Manchester Academic Health Science Centre is a partnership between six NHS organisations in Greater Manchester and The University of Manchester. Manchester AHSC was formally established in July 2008 to underpin the development of Greater Manchester as a world leader in health research. A federation, which interconnects Manchester’s existing research activity and research partnerships, offers huge potential and opportunities and will generate health benefits, economic development, enterprise, innovation and wealth creation in Greater Manchester and the wider North West. www.mahsc.ac.uk/
Source: ICON plc
Katy Davidson, +44-(0)20-706-70-205, kdavidson at webershandwick.com
Related Press Releases
Aha-Soft Releases an Icon Editor With Aqua EffectAugust 16th, 2009 KRASNOYARSK, Russia - Aha-Soft adds Aqua effect to its most famous icon editing tool - IconLover 5. The updated software offers Windows users the ability to create and modify icons and cursors.
CTMM Becomes One of the World's Largest Public-Private Partnerships in Translational Medical ResearchAugust 3rd, 2009 EINDHOVEN, The Netherlands - With today's final approval of a research project into prostate cancer, the Dutch CTMM (Center for Translational Molecular Medicine) today announced the successful completion of 265 million euro funding for translational (bench-to-bedside) medical research, making CTMM one of the largest public-private partnerships in the world. This pivotal point in the organisation's development firmly positions the Netherlands as one of the world's leading destinations for translational biomedical research.
Brand New Conference on Developing 21st Century Military Medical Capabilities to be Held in Abu DhabiAugust 2nd, 2009 ABU DHABI, UAE - The region's first and only summit on military medicine, Defence Healthcare 2009 will be held from 22nd - 25th November 2009 at the Hilton Hotel in Abu Dhabi. Developed in collaboration with global military medical leaders and experts from the British Army, Bahrain Defense Force, Riyadh Military Hospital, UK Royal Army Medical Corps, Swedish Armed Forces Centre for Defence Medicine, NATO Centre of Excellence for Military Medicine and Saudi Arabia Armed Forces Medical Services, this premier event is designed to transform the region's military medical capabilities.
Oscar Award Winner, Dr. A.R. Rahman inaugurates Apollo Children's Hospital - the First Standalone Quaternary Care Paediatric Hospital in the Apollo Hospitals GroupJuly 30th, 2009 CHENNAI, India - Oscar Award Winner, Dr. A.R. Rahman today formally inaugurated the Apollo Children's Hospital, the First Standalone Quaternary Care Paediatric Hospital in the Apollo Hospitals Group.
The Foundation for Research in Osteoporosis and Bone Disease (FROMO) Awards the 2009 Fellowship in Renal Physiology and PathophysiologyJune 28th, 2009 GENEVA -
The Foundation for Research in Osteoporosis and Bone Disease (FROMO) announced the recipients of the 2009 Fellowship in Renal Physiology and Pathophysiology: Andreas Kistler, MD, PhD, Clinical Fellow at the Division of Nephrology of the University Hospital Zurich, Switzerland and Sara Damiano, PhD student in Nephrological Sciences at the Second University of Naples, Italy. The biotechnology company Amgen offered this educational grant to FROMO which is a Foundation based in Geneva to support research and teaching in the field of bone disease, in particular renal osteodystrophy which affects patients with severe renal insufficiency.
ICON Selected to Manage Lilly Clinical Trial Site Set Up and Monitoring in EuropeJune 8th, 2009 DUBLIN - Strategic Partnership Leverages ICON's Extensive European Capabilities
ICON plc, (NASDAQ: ICLR; ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has signed a strategic partnership with Eli Lilly and Company (NYSE: LLY) to manage the company's clinical trial site set up and monitoring in Europe for Lilly managed studies. The agreement, which is subject to the relevant employee consultation processes, is a continuation of Lilly's ongoing transformation of its research and development organisation and follows Lilly's selection of ICON to manage its clinical data management business outside of the US, which was announced in November 2008.
MDS Nordion Opens New Radiopharmaceutical Production Facility in BelgiumMay 27th, 2009 OTTAWA, Canada and FLEURUS, Belgium - Site to Provide Fluorodeoxyglucose (F-18 FDG) for use in Earlier Detection of Disease and Therapy Management
MDS Nordion, a leading global provider of medical isotopes and radiopharmaceuticals used in molecular medicine, today announced the opening of a facility in Fleurus, Belgium for the production of Fluorodeoxyglucose (F-18 FDG), a radiopharmaceutical used in positron emission tomography (PET) imaging. PET imaging produces a three-dimensional image, or picture, of functional processes in the body, such as brain activity, and is a highly accurate and effective method of diagnosing disease and managing patient therapy.
Unit Clothing Mask Up to Combat Swine FluMay 18th, 2009 BRISBANE, Australia - Australia's fastest growing action sports label, Unit Clothing is teetering on the edge of controversy once more following the launch of a campaign to promote its 'Age of Panic' theme. (Photo: www.newscom.com/cgi-bin/prnh/20090519/NY19277 )
Unit has released its own range of face masks and respirators in an effort to combat the global threat of swine flu.
Pharma and Biotech Companies Plug into Singapore's Integrated Research NetworkMay 18th, 2009 ATLANTA - Singapore provides a home for innovation in Asia
Leading pharmaceutical and biotech companies are drawing on Singapore's integrated network of public-sector and academic institutes to enhance their R&D productivity, leverage academic insights and diversify risks. Located at the heart of Asia with a population base that is representative of key Asian ethnic groups, Singapore provides a home-base of innovation for companies to test and develop new solutions for Asia and beyond.
Further 100 Million Euros Allocated to Netherlands-Based R&D Targeting the Early Diagnosis and Treatment of DiseaseMarch 9th, 2009 EINDHOVEN, The Netherlands - The Center for Translational Molecular Medicine (CTMM) - the Dutch
public-private partnership committed to the research and development of new
techniques for the diagnosis and treatment of major diseases - today
announced that eight new research projects will receive funding from the
CTMM. It means that almost 250 million Euros have now been allocated to
Netherlands-based translational projects that could radically improve patient
outcomes for diseases such as Alzheimer's, rheumatoid arthritis, sepsis,
cardiovascular disorders and the most important forms of cancer.
Related News
Bristol-Myers Squibb, Biocon's Syngene open new R and D facility at Biocon ParkMarch 23rd, 2009 BANGALORE - Syngene International, a subsidiary of Indian biotechnology major, BIOCON Ltd, and Bristol-Myers Squibb Company announced today the opening of a fully dedicated research and development facility for Bristol-Myers Squibb in Biocon Park, Bangalore. The 200,000 square-foot facility at Biocon Park is dedicated to helping advance Bristol-Myers Squibb's work in discovery and early drug development, and is currently occupied by 270 researchers.
Appeals court reverses earlier ruling, says Conn. postal facility can display religious itemsAugust 21st, 2009 Court: Religious items OK in Conn. postal facilityMANCHESTER, Conn.
Last major medical facility in Tamil-held territory in Lanka non-functionalMarch 15th, 2009 COLOMBO - The last major medical facility in Tamil-held territory has almost stopped functioning due to medicine shortage, the BBC quoted a Sri Lankan health official, as saying at the weekend.r. T. Varatharaja warned that the closure of the hospital would put the lives of thousands of sick and injured people in the conflict zone at extreme risk.
New testing facility to improve land mine detection equipmentMay 14th, 2009 WASHINGTON - Researchers at the Georgia Institute of Technology have built a test facility to evaluate and enhance sensors designed to detect buried land mines. The unique automated system measures the response of individual electromagnetic induction sensors or arrays of sensors against land mines buried at many possible angles.
Steel company announces plans for Mississippi plant that could bring 50 jobsJuly 17th, 2009 Steel company announces plans for Miss. plantCOLUMBUS, Miss.
Cessna Aircraft announces 2,300 layoffs, closure of Ore. plant as plane orders fallApril 29th, 2009 Cessna announces 2,300 layoffs as orders fallWICHITA, Kan. — Wichita-based Cessna Aircraft Co.
Antique Buddha icon recovered in Himachal PradeshJanuary 6th, 2009 SHIMLA - An antique Buddha icon weighing about 20 kg has been recovered from a Himachal Pradesh village, police said Wednesday. 'We recovered an antique bronze icon of Buddha during a raid at a village in Hamirpur district Monday night,' Hamirpur Superintendent of Police Asif Jalal told IANS.
Second Wyoming soda ash producer announces layoffsAugust 4th, 2009 Wyoming soda ash company announces layoffsGREEN RIVER, Wyo. — Another Wyoming soda ash producer is laying off employees because of the economic downturn.
Vajpayee to spend few more days in hospitalFebruary 3rd, 2009 NEW DELHI - Former prime minister Atal Bihari Vajpayee's chest congestion is better but he will stay at the All India Institute of Medical Sciences (AIIMS) for a few more days, a hospital official said Wednesday. Vajpayee, 85, was admitted to the VIP Intensive Care Unit in AIIMS at about 10 p.m.
Bombardier unveils Indian-built metro carJune 6th, 2009 SALVI - Bombardier Transportation India (BTI) rolled out Bombardier Movia, the first indigenously built metro car from its manufacturing unit, in Savli of Gujarat. Gujarat Chief Minister Narendra Modi launched the roll out of the first metro car.odi congratulated Bombardier's officials for unveiling the first Indian built Metro car in record period.
